IGAN1, IgA nephropathy, 60498

N. diseases: 140; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE IgA nephropathy (IgAN) is the most prevalent primary chronic glomerular disease for which no safe disease-specific therapies currently exist. 31027890 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. 31275309 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide and is an important cause of end-stage renal disease (ESRD). 31272400 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE Here, we report a genetic study of an extended family of Chinese ancestry with focal segmental glomerulosclerosis (FSGS), with one of the affected members also concurrently diagnosed with IgA nephropathy (IgAN). 26039629 2015
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 PosttranslationalModification disease BEFREE A representative animal model of IgA nephropathy (IgAN) is lacking. 28391340 2017
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE This study aimed to evaluate the value of urinary angiostatin levels for assessing disease severity and progression of IgA nephropathy (IgAN). 30943905 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE This study aimed to evaluate the association between ABO blood group and progression of IgA nephropathy (IgAN). 29088730 2017
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. 30635299 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. 31464185 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE In order to understand the role of the alpha3, 4 and/or 5(IV) antigens in TBMD, we used confocal laser scanning microscopy (CLSM) to examine cryosections of renal biopsies from 12 children with TBMD and 11 control children with IgA nephropathy (IgAN) without proteinuria. 12218303 2002
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 GeneticVariation disease BEFREE Our findings expand our understanding on IgAN genetic susceptibility and provide novel biological insights into molecular mechanisms underlying IgAN. 26028593 2015
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and a common cause of end-stage renal disease. 30941137 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE The 80 cases with IgA nephropathy (IgAN) had the highest incidence (59.7%) of de novo or recurrent renal diseases. 29619905 2018
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 PosttranslationalModification disease BEFREE The clinical course of IgA nephropathy (IgAN) is variable and complement activation may predict prognosis. 28814945 2017
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE We integrated eQTL data with an IgA Nephropathy (IgAN) GWAS to perform a transcriptome-wide association study (TWAS). 30057032 2018
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE No single "IgAN gene" has been identified, and it is likely that multiple interacting genes will eventually prove to underlie susceptibility to IgAN and the risk of progressive renal disease. 15156526 2004
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE Although IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, there is no validated tool to predict disease progression. 30980653 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE This work is an immunohistochemical study of Ras expression in normal renal tissue and in membranous glomerulonephritis (MGN), IgA nephropathy (IgAN) and IgA-negative mesangioproliferative glomerulonephritis (MPGN). 14551355 2003
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE IgA nephropathy (IgAN) is the most prevalent cause of primary glomerular disease worldwide, and the cytokine A PRoliferation-Inducing Ligand (APRIL) is emerging as a key player in IgAN pathogenesis and disease progression. 30761651 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide and up to 40% will develop end-stage renal disease (ESRD) within 20 years. 31317004 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE Strong experimental and clinical evidence, the Clinical Practice Guidelines for IgA Nephropathy in Japan, the Oxford Classification, and the Kidney Disease Improving Global Outcomes guidelines have all contributed to the appropriate treatment of IgAN. 30968243 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE We analyzed specimens from patients with diabetic nephropathy (DN), FSGS, IgA nephropathy (IgAN), membranoproliferative GN (MPGN) (<i>n</i>=19-23 for each disease), and a control group (<i>n</i>=14). 28663230 2017
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE Focal segmental glomerular sclerotic lesions in IgA nephropathy (IgAN), considered for years a chronic histologic feature related to proteinuria in remnant nephrons without any active role in the pathogenesis and progression of glomerular damage of IgAN, have been recently reconsidered. 31773265 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 PosttranslationalModification disease BEFREE Studies have shown that the occurrence and development of IgA nephropathy (IgAN) are genetically susceptible, but the relationship between vitamin D receptor (<i>VDR</i>) gene polymorphisms and renal function in IgAN patients is unclear. 31218132 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.100 Biomarker disease BEFREE The efficacy and safety of glucocorticoids for the treatment of patients with IgA nephropathy (IgAN) remains controversial. 30843135 2019